Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease

By afschroeder • March 5, 2026

Curigliano G, Hu X, Dent R, Yonemori K, Barrios CH, Pierga JY, Puglisi F, Ferrero JM, Jung KH, Bagegni NA, Collignon J, Gil-Gil M, Wu X, Andrzejuk-Ćwik A, Schwaederle M, Anand S, Bardia A. Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease. Ann Oncol. 2026 Mar 2:S0923-7534(26)00071-2. doi: 10.1016/j.annonc.2026.02.015. Epub ahead of print. PMID: 41780642.

Tags: burden of disease, endocrine resistance, Hematology/Oncology, metastatic breast cancer, Publications, subgroup analysis, time to progression, trastuzumab deruxtecan

Related Posts

Impact of metastatic pattern and histologic subtype on PD-(L)1 inhibitor efficacy in HER2-negative advanced gastric and gastroesophageal cancer: a meta-analysis

Tai D, Kim KI, Shah P, Park D, Kim L, Li J, Jung C, Guzman S, Brar G, Wu S, Castillo D. Impact of metastatic[...]

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Srour SA, Chahoud J, Drakaki A, Curti BD, Gibney GT, Tang L, Jiang Y, Charmsaz S, Robbins PB, McLeroy J, Severyn CJ, Le Gall JB,[...]

Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD

Goldberg SB, Ahn MJ, Baik C, De Castro Carpeño J, Cho BC, de Langen AJ, Fidler MJ, Goldman JW, Grønberg BH, Akamatsu H, Kim SW,[...]